Doctors are looking for new treatment options for people diagnosed with metastatic hormone receptor-positive, HER2-negative breast cancer that has grown during treatment with hormonal therapy and a CDK4/6 inhibitor. Dr. Virginia Kaklamani is part of the team investigating elacestrant, an oral medicine, to see if offers more benefits than Faslodex (chemical name: fulvestrant), which is the current standard of care.
Listen to the podcast to hear Dr. Kaklamani explain:

the type of medicine elacestrant is and how it works

why it’s important that elacestrant showed benefits for breast cancers with an ESR1 mutation

when we might hear if elacestrant is approved by the U.S. Food and Drug Administration (FDA)